US Patent

US11439597 — Formulations of (R)-2-amino-3-phenylpropyl carbamate

Formulation · Assigned to Axsome Malta Ltd · Expires 2037-09-05 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate, also known as solriamfetol hydrochloride, for treating disorders.

USPTO Abstract

The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

Patent Metadata

Patent number: US11439597
Jurisdiction: US
Classification: Formulation
Expires: 2037-09-05
Drug substance claim: No
Drug product claim: Yes
Assignee: Axsome Malta Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.